Public Citizen criticizes Lunesta pricing

Share this article:
Consumer advocacy group Public Citizen has made Massachusetts pharmaceutical company Sepracor its latest industry target, criticizing the company over pricing of its sleep aid Lunesta.
According to a Bloomberg News report, Sepracor charges nearly $99 for a 30-day supply of Lunesta versus $87.99 for a 30-day supply of Sanofi-Aventis' Ambien, a primary competitor and the global sales leader.
Generic versions of Ambien sell for $12.99 for a 30-day supply, Public Citizen said.
The group also claimed Sepracor gained approval for Lunesta despite a concern about cancer risks, after a senior FDA official overruled the objections and the agency instead sought more information. 
Sepracor told Bloomberg News that Public Citizen's assertions were wrong and that the FDA issued a "universal decision to approve this drug."
Sepracor is hoping Lunesta will achieve positive results, spending $100 million to market the drug and boosting its work force by 900 employees to help sell it.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies